Overview
One blister strip packaging along with instructions for use in a pack of cardboard.
In a dark place at a temperature of 2 ° C to 8 ° C. Do not freeze. Avoid direct contact with the freezer or frozen objects.
After the start of use, store no more than 4 weeks at a temperature not exceeding 25 ° C (but not in the refrigerator).
Insulin glargin: instructions for use and reviews
Latin name: Insulin glargine
Active ingredient: insulin glargine (Insulin glargine)
Producer: LLC Endogenics (Russia), Gan & Lee Pharmaceuticals (Gan & Lee Fharmaceutical) (China)
Update description and photo: 07/11/2019
Glulin insulin - a hypoglycemic drug, a long-acting insulin analogue.
The drug is available in the form of a solution for subcutaneous (s / c) administration: a clear, colorless liquid (3 ml each in glass transparent cartridges without color, 1 or 5 cartridges in blister packs, 1 pack in a cardboard bundle; 10 ml in transparent glass bottles without color, in a cardboard bundle 1 bottle and instructions for use of Insulin glargin).
1 ml of solution contains:
show substance: insulin glargine - 100 PIECES (unit of action), which is equivalent to 3.64 mg; - auxiliary components: zinc chloride, metacresol, glycerol, sodium hydroxide, hydrochloric acid, water for injection.
Glulin insulin is a hypoglycemic drug, a long-acting insulin analogue.
The active substance of the drug - insulin glargine - an analog of human insulin obtained by recombination of DNA (deoxyribonucleic acid) strains of K12 bacteria of the species Escherichia coli.
Insulin glargine is characterized by low solubility in a neutral environment. The complete solubility of for treating active substance in the composition of the drug is achieved due to the content of hydrochloric acid and sodium hydroxide. Their amount provides the solution with an acid reaction - pH (acidity) 4, which, after the drug is introduced into the subcutaneous fat, is neutralized. As a result, microprecipitate are formed, from which there is a constant release of small amounts of insulin glargine, which provides the drug with a prolonged action and a smooth predictable profile of the concentration-time curve.
The kinetics of binding of insulin glargine and its active metabolites M1 and M2 to specific insulin receptors is close to that of human insulin, which determines the ability of insulin glargine to have a biological effect similar to endogenous insulin.
The main action of insulin glargine is the regulation of glucose metabolism. By inhibiting the synthesis of glucose in the liver and stimulating the Basaglar of glucose by adipose tissue, skeletal muscle and other peripheral tissues, it helps to reduce the concentration of glucose in the blood. Suppresses lipolysis in Basaglar and delays proteolysis, while increasing protein formation.
The prolonged action of insulin glargine is due to a reduced rate of its absorption. The average duration of insulin glargine after subcutaneous administration is 24 hours, the maximum is 29 hours. The effect of the drug occurs approximately 1 Basaglar after administration. It should be borne in mind that the period of action of insulin glargine in different patients or in one patient can vary significantly.
The effectiveness of the drug in children with type 1 diabetes mellitus over the age of 2 years has been confirmed. When using insulin glargine, there is a lower incidence of clinical manifestations of hypoglycemia during the day and at night in children 2-6 years old compared with insulin-isofan.
The results of a study lasting 5 years indicate that in patients with type 2 diabetes mellitus, the use of insulin glargine or insulin-isophan has the same effect on the progression of diabetic retinopathy.
Compared to human insulin, the affinity of insulin glargine for the IGF-1 receptor (insulin-like growth factor 1) is about 5–8 times higher, and the active metabolites M1 and M2 are slightly less.
In patients with type 1 diabetes mellitus, the total concentration of insulin glargine and its metabolites is significantly lower than the level required for half-maximum binding to IGF-1 receptors, followed by activation of the mitogenic proliferative pathway, which is triggered via IGF-1 receptors. In Basaglar to physiological concentrations of endogenous IGF-1, the therapeutic insulin concentration achieved with glargine insulin treatment is significantly lower than the pharmacological concentration sufficient to activate the mitogenic proliferative pathway.
The results of a clinical study indicate that when using insulin glargine in patients with a high risk of developing cardiovascular disease and impaired glucose tolerance, impaired fasting glucose or early type 2 diabetes, the likelihood of developing cardiovascular complications or cardiovascular mortality is comparable with that of standard hypoglycemic therapy. No differences were found in the rates of any component constituting the end points, the combined indicator of microvascular outcomes, mortality from all causes.
Compared with insulin-isofan, after subcutaneous administration of insulin glargine, slower and longer absorption is observed, there is no peak in concentration.
Against the background of a single daily subcutaneous administration of Insulin glargine, the equilibrium concentration of the active substance in the blood is reached after 2–4 days.
